Monday, January 14, 2019

1 in 4 Ontario Physicians are 'high testers'

ICES
Ontario family doctors are "high testers," ordering more imaging or lab tests, with their patients more likely to be diagnosed with thyroid or prostate cancers that may not need treatment: Cancer Medicine.

Saturday, December 22, 2018

Flu Watch 2018







For more information on the flu, see the Flu (influenza) web page. 
This report is available on the Government of Canada Influenza webpage. 

Wednesday, November 21, 2018

Healthcare report Ontario

Thursday, November 1, 2018

PART LXI: injection


Nov. 1, 2018
We're on to appointment #61. Happily, it has all changed. For this, and the next appointment, hubby only needs go to our GP's office for his needle.

We are aware of health issues, which are really side effects of this chemical-induced menopause. I would bet that this result is more a factor of weight gain, the change in metabolism, bone density loss, and the mild depression from the hormone changes.

Hubby is exercising, lost 10 lbs. prior to treatment, is going to a naturopath for calcium supplements, to combat the bone density loss.

Antihormone Therapy Linked with Higher Heart Failure Risk in Prostate Cancer Patients
Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer. 
In The Journal of Clinical Pharmacology study, incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 and 1.89 for androgen deprivation therapy users and nonusers, respectively. (A person-year is the number of years of follow-up multiplied by the number of people in the study.) The study included data from the Taiwan Longitudinal Health Insurance Database 2005 on 1244 patient who received androgen deprivation therapy and 1806 patients who did not.
 “The results of our study provide information for prostate cancer patients to be aware of the potential heart failure risk of receiving androgen deprivation therapy,” the authors wrote. “We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for prostate cancer patients receiving androgen deprivation therapy.”

Monday, October 1, 2018

Global child mortality

Tuesday, September 25, 2018

Stimulant and drug use in Ontario

Landscape of Prescription Stimulant Use

Stimulants are a class of medications approved in Canada for the treatment of attention-deficit/hyperactivity disorder (ADHD) and sleeping disorders (e.g. narcolepsy). The objective of this report is to describe patterns of prescription stimulant use in Ontario over time, by age and gender, and to explore how the use of these medications differs across the province.
This research report is a project identified by the ODPRN Citizens’ Panel (CP) as being of joint interest to policymakers, researchers and the general public. The CP members identified the research questions of interest, chose the measures to be included in the report, provided interpretations on study findings and reviewed the final report.

Access the full report and associated resources:

Thursday, September 6, 2018

The Opioid Chapters – life stories

A new joint multimedia project of the Ontario Drug Policy Research Network (ODPRN) and the website Healthy Debate. Please see details below and share with your respective networks.

“Drugs were in my system since I was two years old,” says Henry, a community services worker who lives in Ottawa. “The only difference between me and others is that they went to school and had a childhood. Yeah, there are the opioids. But there is also the life line that gets you there.”

The Opioid Chapters features Henry’s story along with those of 10 other people whose lives have been profoundly affected by opioids. A joint project of the Ontario Drug Policy and Research Network (ODPRN) and the website Healthy Debate, this multimedia online series features powerful first-person narratives from people who take opioids for chronic pain, those with an opioid use disorder, and providers who work with both.

The stories reveal the singularity of each person’s experience with respect to opioids. Benjamin, a young father and student, is a strong proponent of harm reduction. For Fran, the best way forward from a history of addiction and ongoing chronic pain is Suboxone. Rupa, a family physician, partners with patients in an effort to help them taper off high doses of opioids. Michael has had chronic pain for 15 years and tried multiple treatments; opioids are what allow him to function. 

Taken together, these accounts also reveal the complexity of addressing what many are today calling an opioid crisis. There is no one solution. But to begin to make positive change, we need to understand the unique impact opioids have on different people’s lives. The Opioid Chapters offers a window into the difficult journeys and hard-won successes of people affected by opioids, and the importance of listening carefully to their experiences.

Wednesday, July 25, 2018

Overall cancer death rates

Greater Efforts Are Needed to Address ‘Financial Toxicity’ of Cancer Treatment

 In addition to facing new concerns about their health, individuals who are diagnosed with cancer often worry about the financial burdens of treatment. A new study indicates that many patients feel that such ‘financial toxicity’ is not adequately addressed by their doctors and other clinicians. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

The survey also revealed that many patients desired to talk to providers about the financial impact of cancer: 
  • 15.2 percent of whites, 
  • 31.1 percent of blacks, 
  • 30.3 percent of Latinas, 
  • and 25.4 percent of Asians. 
Unmet patient needs for engagement with doctors about financial concerns were common. Of 945 women who worried about finances, 679 (72.8 percent) indicated that doctors and their staff did not help. Of 523 women who desired to talk to providers about the impact of breast cancer on employment or finances, 283 (55.4 percent) reported no relevant discussion.

Full Citation: “Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer.” CANCER; Published Online: July 23, 2018 (DOI: 10.1002/cncr.31532).

Wednesday, July 11, 2018

28th annual conference for the International Cannabinoid Research Society

Image result for tweed medical marijuanaCanada is set to legalize marijuana.  The new Canadian laws forbid celebrities advertising for companies.

Our nearby facility, Tweed - Canadian Cannabis,  has been producing medical marijuana for a few years. Their packaging is getting to be pretty sweet.
Image result for tweed medical marijuana
This would be an interesting conference. Much research is being done.



Cannabinoid Research Company ebbu Returns to Annual Meeting of World’s Top Cannabis Researchers, Presenting New Study Findings on Mood Effects

LEIDEN, The Netherlands—July 11, 2018—Pioneering cannabis science firm ebbu has released findings from its innovative clinical research into the mood effects of cannabis. These findings were presented this week at the 28th annual conference for the International Cannabinoid Research Society (ICRS), where the world’s foremost cannabis researchers convened to discuss ongoing studies and findings with their peers, gain valuable feedback and forge partnerships with the goal of developing a deeper understanding of how the body processes and is affected by cannabis.

ebbu Director of Clinical Pharmacology
Dr. Jonathan Martin 

About ebbu
Colorado-based ebbu is generating clinically-proven cannabinoid formulations for medicine, and mainstreaming hemp and adult-use cannabis by creating consistent, predictable sensations. ebbu partners with category-leading companies to power infused products using its patented, lab-tested and science-based platform. For more information, visit ebbu.com